134 related articles for article (PubMed ID: 16093866)
1. 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma.
Borbath I; Lhommel R; Bittich L; Goffette P; Annet L; Van Beers BE; Bonny MA; Pauwels S; Horsmans Y
Eur J Gastroenterol Hepatol; 2005 Sep; 17(9):905-10. PubMed ID: 16093866
[TBL] [Abstract][Full Text] [Related]
2. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates.
Keng GH; Sundram FX; Yu SW; Somanesan S; Premaraj J; Oon CJ; Kwok R; Htoo MM
Ann Acad Med Singap; 2002 May; 31(3):382-6. PubMed ID: 12061301
[TBL] [Abstract][Full Text] [Related]
3. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience.
Lintia-Gaultier A; Perret C; Ansquer C; Eugène T; Kraeber-Bodéré F; Frampas E
Nucl Med Commun; 2013 Jul; 34(7):674-81. PubMed ID: 23587835
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
Raoul JL; Guyader D; Bretagne JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M
J Nucl Med; 1994 Nov; 35(11):1782-7. PubMed ID: 7525901
[TBL] [Abstract][Full Text] [Related]
5. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
[TBL] [Abstract][Full Text] [Related]
6. Effect of a 188 Re-SSS lipiodol/131I-lipiodol mixture, 188 Re-SSS lipiodol alone or 131I-lipiodol alone on the survival of rats with hepatocellular carcinoma.
Garin E; Rakotonirina H; Lejeune F; Denizot B; Roux J; Noiret N; Mesbah H; Herry JY; Bourguet P; Lejeune JJ
Nucl Med Commun; 2006 Apr; 27(4):363-9. PubMed ID: 16531923
[TBL] [Abstract][Full Text] [Related]
7. 131-iodine Lipiodol therapy in hepatocellular carcinoma.
Raoul JL; Boucher E; Roland V; Garin E
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):348-55. PubMed ID: 19521315
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study.
Brans B; De Winter F; Defreyne L; Troisi R; Vanlangenhove P; Van Vlierberghe H; Lambert B; Praet M; de Hemptinne B; Dierckx RA
Cancer Biother Radiopharm; 2001 Aug; 16(4):333-8. PubMed ID: 11603004
[TBL] [Abstract][Full Text] [Related]
9. 131I lipiodol therapy for unresectable hepatocellular carcinoma.
Rindani RB; Hugh TJ; Roche J; Roach PJ; Smith RC
ANZ J Surg; 2002 Mar; 72(3):210-4. PubMed ID: 12071454
[TBL] [Abstract][Full Text] [Related]
10. Radionuclide therapy of hepatocellular carcinoma.
Keng GH; Sundram FX
Ann Acad Med Singap; 2003 Jul; 32(4):518-24. PubMed ID: 12968558
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma.
Bhattacharya S; Novell JR; Dusheiko GM; Hilson AJ; Dick R; Hobbs KE
Cancer; 1995 Dec; 76(11):2202-10. PubMed ID: 8635022
[TBL] [Abstract][Full Text] [Related]
12. Therapy of hepatocellular carcinoma with iodine-131-lipiodol. Results in a large German cohort.
Risse JH; Rabe C; Pauleit D; Reichmann K; Menzel C; Grünwald F; Strunk H; Biersack HJ; Palmedo H
Nuklearmedizin; 2006; 45(4):185-92. PubMed ID: 16964345
[TBL] [Abstract][Full Text] [Related]
13. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma.
Raoul JL; Guyader D; Bretagne JF; Heautot JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M
Hepatology; 1997 Nov; 26(5):1156-61. PubMed ID: 9362356
[TBL] [Abstract][Full Text] [Related]
15. Review article: intra-arterial treatments in patients with hepatocellular carcinoma.
Trinchet JC; Ganne-Carrie N; Beaugrand M
Aliment Pharmacol Ther; 2003 Jun; 17 Suppl 2():111-8. PubMed ID: 12786622
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG-PET and histopathology in 131I-lipiodol treatment for primary liver cancer.
Risse JH; Pauleit D; Bender H; Rabe C; Fischer HP; Biersack HJ; Bucerius J
Cancer Biother Radiopharm; 2009 Aug; 24(4):445-52. PubMed ID: 19694579
[TBL] [Abstract][Full Text] [Related]
17. Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma.
Chua TC; Chu F; Butler SP; Quinn RJ; Glenn D; Liauw W; Morris DL
Cancer; 2010 Sep; 116(17):4069-77. PubMed ID: 20564150
[TBL] [Abstract][Full Text] [Related]
18. Selective radionuclide localisation in primary liver tumours (pilot study).
Novell JR; Green AJ; Hilson AJ; Dusheiko G; Dick R; Hobbs KE
HPB Surg; 1994; 7(3):185-99; discussion 200. PubMed ID: 8155585
[TBL] [Abstract][Full Text] [Related]
19. Ablation of recurrent primary liver cancer using 131I-lipiodol.
Novell R; Hilson A; Hobbs K
Postgrad Med J; 1991 Apr; 67(786):393-5. PubMed ID: 1648718
[TBL] [Abstract][Full Text] [Related]
20. 131I thyroid uptake in patients treated with 131I-Lipiodol for hepatocellular carcinoma.
Toubeau M; Touzery C; Berriolo-Riedinger A; Cochet A; Brunotte F; Bedenne L; Cercueil JP; Krause D
Eur J Nucl Med; 2001 May; 28(5):669-70. PubMed ID: 11383874
[No Abstract] [Full Text] [Related]
[Next] [New Search]
